Nucleus RadioPharma Secures Investment from AstraZeneca
Nucleus RadioPharma announced the closing of an extended Series A funding round with the addition of new investor AstraZeneca.
Stay updated with breaking news from Tyrell Rivers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nucleus RadioPharma announced the closing of an extended Series A funding round with the addition of new investor AstraZeneca.
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca
. Cellectis announced completion of the additional equity investment of $140M by AstraZeneca . Cash position of $143 million as of March 31
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 -- Cellectis a clinical-stage biotechnology...
Cellectis said on Monday that AstraZeneca had finalized its additional $140 million investment in the company, in line with the deal announced last November.The biotech company, which specializes in...